Last update 01 Nov 2024

Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII

Private Company|

Bergamo, Italy

Private Company|

Bergamo, Italy

Last update 01 Nov 2024

Overview

Pipeline

Deal

Translational Medicine

Overview

Clinical Trials associated with Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII

NCT02585622 / Active, not recruitingPhase 1/2IIT

Novel Stromal Cell Therapy for Diabetic Kidney Disease (NEPHSTROM Study)

The study will investigate, primarily, the safety, feasibility and tolerability and, secondarily, the preliminary efficacy of an allogeneic bone marrow-derived Mesenchymal Stromal Cell (MSC) therapy (ORBCEL-M) in study subjects with type 2 diabetes (T2D) and progressive diabetic kidney disease (DKD).

Start Date11 Dec 2017

Sponsor / Collaborator

Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII

[+6]

100 Clinical Results associated with Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII

0 Patents (Medical) associated with Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII

203

Literatures (Medical) associated with Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII

01 Oct 2024·American Journal of Obstetrics and Gynecology

Intravenous immunoglobulin for the treatment of severe maternal alloimmunization: individual patient data meta-analysis

Review

Author: Maurice, Paul ; Mustafa, Hiba J ; Zwiers, Carolien ; Pagani, Giorgio ; Flood, Anna ; D'Antonio, Francesco ; Maisonneuve, Emeline ; Jouannic, Jean-Marie ; Shamshirsaz, Alireza A ; Sambatur, Enaja V ; Verweij, Joanne E J T ; Khalil, Asma

OBJECTIVEThis study aimed to investigate the outcomes associated with the administration of maternal intravenous immunoglobulin in high-risk red blood cell-alloimmunized pregnancies.DATA SOURCESMedline, Embase, and Cochrane Library were systematically searched until June 2023.STUDY ELIGIBILITY CRITERIAThis review included studies reporting on pregnancies with severe red blood cell alloimmunization, defined as either a previous fetal or neonatal death or the need for intrauterine transfusion before 24 weeks of gestation in the previous pregnancy as a result of hemolytic disease of the fetus and newborn.METHODSCases were pregnancies that received intravenous immunoglobulin, whereas controls did not. Individual patient data meta-analysis was performed using the Bayesian framework.RESULTSIndividual patient data analysis included 8 studies consisting of 97 cases and 97 controls. Intravenous immunoglobulin was associated with prolonged delta gestational age at the first intrauterine transfusion (gestational age of current pregnancy - gestational age at previous pregnancy) (mean difference, 3.19 weeks; 95% credible interval, 1.28-5.05), prolonged gestational age at the first intrauterine transfusion (mean difference, 1.32 weeks; 95% credible interval, 0.08-2.50), reduced risk of fetal hydrops at the time of first intrauterine transfusion (incidence rate ratio, 0.19; 95% credible interval, 0.07-0.45), reduced risk of fetal demise (incidence rate ratio, 0.23; 95% credible interval, 0.10-0.47), higher chances of live birth at ≥28 weeks (incidence rate ratio, 1.88; 95% credible interval, 1.31-2.69;), higher chances of live birth at ≥32 weeks (incidence rate ratio, 1.93; 95% credible interval, 1.32-2.83), and higher chances of survival at birth (incidence rate ratio, 1.82; 95% credible interval, 1.30-2.61). There was no substantial difference in the number of intrauterine transfusions, hemoglobin level at birth, bilirubin level at birth, or survival at hospital discharge for live births.CONCLUSIONIntravenous immunoglobulin treatment in pregnancies at risk of severe early hemolytic disease of the fetus and newborn seems to have a clinically relevant beneficial effect on the course and severity of the disease.

01 Oct 2024·Journal of the American College of Cardiology

Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart Failure

Article

Author: Ito, Hiroshi ; Senni, Michele ; Borlaug, Barry A ; Abhayaratna, Walter P. ; Wolf, Dennis ; Wang, Xiaowen ; Borlaug, Barry A. ; Kitzman, Dalane W ; Abhayaratna, Walter P ; Solomon, Scott D. ; Rasmussen, Søren ; Petrie, Mark C. ; Merkely, Bela ; Nygaard Einfeldt, Mette ; Ahmed, Fozia Z ; Ostrominski, John W ; Petrie, Mark C ; Davies, Melanie J. ; Kosiborod, Mikhail N. ; Ahmed, Fozia Z. ; Kosiborod, Mikhail N ; Ben-Gal, Tuvia ; Verma, Subodh ; Chopra, Vijay ; Abildstrøm, Steen Z. ; Shah, Sanjiv J. ; Shah, Sanjiv J ; Solomon, Scott D ; Kitzman, Dalane W. ; van der Meer, Peter ; Butler, Javed ; Abildstrøm, Steen Z ; Ostrominski, John W. ; Davies, Melanie J ; Núñez, Julio

BACKGROUNDObesity is associated with adverse cardiac remodeling and is a key driver for the development and progression of heart failure (HF). Once-weekly semaglutide (2.4 mg) has been shown to improve HF-related symptoms and physical limitations, body weight, and exercise function in patients with obesity-related heart failure with preserved ejection fraction (HFpEF), but the effects of semaglutide on cardiac structure and function in this population remain unknown.OBJECTIVESIn this echocardiography substudy of the STEP-HFpEF Program, we evaluated treatment effects of once-weekly semaglutide (2.4 mg) vs placebo on cardiac structure and function.METHODSEchocardiography at randomization and 52 weeks was performed in 491 of 1,145 participants (43%) in the STEP-HFpEF Program (pooled STEP-HFpEF [Semaglutide Treatment Effect in People with Obesity and HFpEF] and STEP-HFpEF DM [Semaglutide Treatment Effect in People with Obesity, HFpEF, and Type 2 Diabetes] trials). The prespecified primary outcome was change in left atrial (LA) volume, with changes in other echocardiography parameters evaluated as secondary outcomes. Treatment effects of semaglutide vs placebo were assessed using analysis of covariance stratified by trial and body mass index, with adjustment for baseline parameter values.RESULTSOverall, baseline clinical and echocardiographic characteristics were balanced among those receiving semaglutide (n = 253) and placebo (n = 238). Between baseline and 52 weeks, semaglutide attenuated progression of LA remodeling (estimated mean difference [EMD] in LA volume, -6.13 mL; 95% CI: -9.85 to -2.41 mL; P = 0.0013) and right ventricular (RV) enlargement (EMD in RV end-diastolic area: -1.99 cm²; 95% CI: -3.60 to -0.38 cm²; P = 0.016; EMD in RV end-systolic area: -1.41 cm²; 95% CI: -2.42 to -0.40] cm²; P = 0.0064) compared with placebo. Semaglutide additionally improved E-wave velocity (EMD: -5.63 cm/s; 95% CI: -9.42 to -1.84 cm/s; P = 0.0037), E/A (early/late mitral inflow velocity) ratio (EMD: -0.14; 95% CI: -0.24 to -0.04; P = 0.0075), and E/e' (early mitral inflow velocity/early diastolic mitral annular velocity) average (EMD: -0.79; 95% CI: -1.60 to 0.01; P = 0.05). These associations were not modified by diabetes or atrial fibrillation status. Semaglutide did not significantly affect left ventricular dimensions, mass, or systolic function. Greater weight loss with semaglutide was associated with greater reduction in LA volume (P_interaction = 0.033) but not with changes in E-wave velocity, E/e' average, or RV end-diastolic area.CONCLUSIONSIn the STEP-HFpEF Program echocardiography substudy, semaglutide appeared to improve adverse cardiac remodeling compared with placebo, further suggesting that treatment with semaglutide may be disease modifying among patients with obesity-related HFpEF. (Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity [STEP-HFpEF]; NCT04788511; Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes [STEP-HFpEF DM]; NCT04916470).

01 Sep 2024·Infezioni in Medicina

Diagnostic role of CD64 expression on neutrophils as biomarker for blood stream infection in liver cirrhosis: some preliminary findings

Article

Author: Colussi, Gian Luca ; Tonizzo, Maurizio ; Grazioli, Silvia ; Grembiale, Alessandro ; Bramuzzo, Igor ; Sabena, Anna ; Pontoni, Elisa ; Doretto, Paolo ; Crapis, Massimo ; Balbi, Massimiliano ; Pratesi, Chiara ; Basaglia, Giancarlo ; Venturini, Sergio ; Fagiuoli, Stefano ; Costa, Elena Garlatti ; Villalta, Danilo ; Barbato, Giuseppe ; Avolio, Manuela

BackgroundThe expression of CD64 on neutrophils (nCD64), measured using flow cytometry, has been proposed as a biomarker for bloodstream infections (BSI). However, data regarding its use in the setting of liver cirrhosis are lacking.MethodsWe compared nCD64 levels in 15 cirrhotic patients with BSI to those in 19 controls, including outpatients with stable decompensated cirrhosis without infection. Additionally, we compared nCD64 with C-reactive protein (CRP) and procalcitonin (PCT) in infected hospitalized cirrhotic patients.ResultsCirrhotic patients with infection had higher levels of nCD64 compared to controls (6.0 [5.4-7.1] vs. 2.0 [1.5-2.2]; p<0.001). Among infected patients, a correlation between nCD64 (AUC=0.934 [0.875-0.982 95% CI]), CRP (AUC=0.972 [0.942-0.993 95% CI]), and PCT (AUC=0.859 [0.739-0.953 95% CI]) was observed. However, in our sample of cirrhotic individuals, nCD64 values were not significantly different between patients with worse prognosis and those with positive outcomes (p=0.448), and its expression was not influenced by Gram stain.ConclusionsIn our cohort, nCD64 appears to be a promising new biomarker for BSI. Additional prospective studies are needed to confirm its role and limitations in conjunction with other biomarkers and rapid microbiology in the diagnostic multidisciplinary pathway for septic cirrhotic patients.

100 Deals associated with Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII

100 Translational Medicine associated with Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 17 Nov 2024

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis